Osteoporosis is characterized by decreased bone mineral density and increased risk of fracture. Raloxifene is one of the treatments of osteoporosis. However, the responses were variable among patients. Previous studies revealed that the genetic variants are involved in the regulation of treatment outcomes. To date, studies that evaluate the influence of genes across all genome on the raloxifene treatment response are still limited. In this study, a total of 41 postmenopausal osteoporosis patients under regular raloxifene treatment were included. Gene-based analysis using MAGMA was applied to investigate the genetic association with the bone mineral density response to raloxifene at the lumbar spine or femoral neck site. Results from gene-based analysis indicated several genes (GHRHR, ABHD8, and TMPRSS6) related to the responses of raloxifene. Besides, the pathways of iron ion homeostasis, osteoblast differentiation, and platelet morphogenesis were enriched which implies that these pathways might be relatively susceptible to raloxifene treatment outcome. Our study provided a novel insight into the response to raloxifene.

中文翻译：

---

雷洛昔芬在绝经后女性骨质疏松症中的药物基因组学研究。

骨质疏松症的特征是骨矿物质密度降低和骨折风险增加。雷洛昔芬是骨质疏松症的治疗方法之一。然而，反应在患者之间是可变的。先前的研究表明，遗传变异参与治疗结果的调节。迄今为止，评估基因在所有基因组上对雷洛昔芬治疗反应的影响的研究仍然有限。在这项研究中，总共41名接受常规雷洛昔芬治疗的绝经后骨质疏松患者。应用基于MAGMA的基于基因的分析来研究与腰椎或股骨颈部位对雷洛昔芬的骨矿物质密度响应的遗传关联。基于基因的分析结果表明有几个基因（GHRHR，ABHD8和TMPRSS6）与雷洛昔芬的反应有关。此外，铁离子稳态，成骨细胞分化和血小板形态发生的途径被丰富了，这意味着这些途径可能相对易受雷洛昔芬治疗的影响。我们的研究为对雷洛昔芬的反应提供了新颖的见解。